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A Pathogenic Role for IgE in Autoimmunity: Bullous
Pemphigoid IgE Reproduces the Early Phase of Lesion
Development in Human Skin Grafted to nu/nu Mice
Janet A. Fairley1,4, Christopher T. Burnett1, Chang-Ling Fu1, David L. Larson2, Matthew G. Fleming1 and
George J. Giudice1,3
Bullous pemphigoid (BP) is an autoimmune disease characterized by subepidermal blistering. Based
on previous work, IgG autoantibodies directed against BP180 are thought to be the primary pathogenic
agent in BP. In addition to these IgG autoantibodies, however, most BP patients produce IgE class
autoantibodies that also react with BP180, and total IgE levels are often elevated in this disease. To directly
test whether BP IgE is pathogenic, 6 ng of total IgE isolated from two BP and two normal sera were injected
into human skin grafted onto athymic, nude mice. Twenty-four hours after injection, erythematous,
elevated plaques were observed in all human skin grafts receiving BP IgE (n¼ 11), but not control IgE (n¼ 9).
Histologic and ultrastructural examination of the lesions showed engorgement of blood vessels and a dermal
infiltrate composed of neutrophils, eosinophils, and mast cells, many of which were degranulated. At a higher
dose of BP IgE (47 ng), histological separation of the epidermis from the dermis was observed in two of the three
grafts. The BP IgE-induced erythematous plaques were reminiscent of those clinically seen in BP. This provides
early evidence of a direct demonstration of a pathogenic role for IgE class autoantibodies in a human
autoimmune disease.
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INTRODUCTION
Bullous pemphigoid (BP) is an acquired blistering skin disease
characterized by a humoral autoimmune reaction directed
against components of the hemidesmosome, a cellular
structure involved in anchoring the epidermis to the dermis.
The initial phase of lesion development in BP is characterized
by urticarial plaques consisting of dermal edema accompanied
by eosinophilic infiltration of the upper dermis, termed
eosinophilic spongiosis. As the lesions progress, there is
clinical development of tense, fluid-filled vesicles, which
correspond histologically to a separation of the skin through
the basement membrane zone (BMZ). In addition, there is a
superficial and deep perivascular infiltrate of many eosino-
phils, lymphocytes, mast cells, and neutrophils.
The seminal work of Beutner and Jordon (Jordon et al.,
1967), in which immunoglobulins and C3 were shown to be
deposited along the cutaneous BMZ of BP patients, pointed to
the immunological basis of this disease. These investigators
were also the first to identify anti-BMZ antibodies in the sera
of BP patients. The primary antigenic targets of BP
autoantibodies were subsequently identified as two hemi-
desmosomal proteins, BPAG1 (Stanley et al., 1981) and
BP180 (also termed collagen XVII and BPAG2) (Labib et al.,
1986; Diaz et al., 1990; Giudice et al., 1992). BPAG1 is a
component of the intracellular hemidesmosomal plaque
(Tanaka et al., 1991), and its role in pathogenicity remains
unknown. In contrast, numerous studies using in vivo and
in vitro models of BP strongly suggest that antibodies directed
against BP180 are of primary pathogenic importance
(reviewed in Liu and Diaz 2001). Injection of IgG antibodies
against BP180 into neonatal mouse skin initiates an
inflammatory reaction resulting in skin fragility at the level
of the BMZ; however, urticarial plaque formation, recruit-
ment of eosinophils and gross clinical blistering are not seen.
Likewise, the injection of human BP IgG into human skin
transplanted onto SCID mice leads to histological subepider-
mal separation, but no clinical disease that mimics BP or any
eosinophilic infiltration (Zillikens et al., 2001).
The majority of the experimental work on BP has focused
on IgG class autoantibodies, even though it has been long
known that there is also an IgE response associated with this
disease (Provost and Tomasi, 1974). The presence of IgE
autoantibodies in BP is particularly interesting in light of the
fact that BP patients typically have an early urticarial phase of
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the eruption, and the role of IgE-mediated degranulation of
mast cells in allergic forms of urticaria is well established
(Friedmann 1999). During this early phase of BP, patients
have large urticarial plaques but may manifest few, if any,
blisters. Sequential histological examination of the skin of BP
patients during the development of individual lesions has
shown that mast cell degranulation is the earliest event that
can be identified histologically, followed by lymphocytic
infiltration and later eosinophil and neutrophil migration into
the lesion (Wintroub et al., 1978; Dvorak et al., 1982).
Further evidence for mast cell degranulation is the presence
of eotaxin (Shrikhande et al., 2000) and tryptase (D’Auria
et al., 2000) in the blister fluid of BP lesions. Also of note,
mast cell tryptase has been shown experimentally to be
capable of causing epidermal–dermal separation (Kaminska
et al., 1999).
Total circulating IgE levels are elevated in 70% of untreated
BP patients (Dimson et al., 2003, Arbesman et al., 1974), and
IgE class autoantibodies directed against BP180 can be
detected in 90% of untreated BP patients (Dimson et al.,
2003). Moreover, basophils isolated from the peripheral blood
of untreated BP patients were shown to degranulate when
exposed to recombinant BP180 (Dimson et al., 2003). The
important implication of this finding is that IgE autoantibodies
specific for BP180 are present at the surface of basophils,
bound to the IgE receptor. We have hypothesized that an
analogous process is occurring in mast cells in the skin of BP
patients, and that autoantigen-induced mast cell degranula-
tion is a key trigger for the urticarial phase of BP. To test the
pathogenic potential of IgE class autoantibodies in BP, we
isolated IgE from BP patients’ sera and injected it into human
skin transplanted to athymic nude (nu/nu) mice.
RESULTS
Levels of total IgE are elevated in BP sera
Total serum IgE levels were determined by a standard capture
ELISA. The IgE concentrations in sera BP-W7714 and BP-
G5554 were 18 and 4 mg/ml, respectively. Compared to the
upper limit of the normal range for serum IgE (240 ng/ml), the
IgE levels for BP-W7714 and BP-G5554 are 75 and 17-fold
higher, respectively. Western blot analysis revealed that both
BP sera contained IgE that reacts with the NC16A domain of
type XVII collagen (see below).
Purified BP IgE continues to bind to NC16A, the BMZ, and mast
cells
IgE was purified from sera BP-W7714 and BP-G5554 using a
combination of negative and positive selection (see Materials
and Methods). This purification scheme yielded approxi-
mately 10,000-fold purification of IgE relative to IgG. The IgE
and IgG concentrations in both of the purified BP IgE
preparations were 350–500 and 10–25 ng/ml, respectively.
The IgE continued to bind to the BMZ of human skin
and cutaneous mast cells, as determined by immunofluore-
scence using species-specific FITC-conjugated anti-IgE
(Chemicon, Temecula, CA) (Figure 1a). The purified IgE also
retained its ability to bind to BP180 by immunoblotting
(Figure 1b).
Injection of BP IgE produces urticarial plaques and mast cell
degranulation in human skin grafts
The model system that was used to test the pathogenicity of
BP IgE involved grafting human skin onto the backs of nude
mice. Cryosections of 2-week grafts exhibited normal
labeling patterns with antibodies to human BP180, laminin
5, and collagen VII, thus showing the integrity of the BMZ
(data not shown). Retention of human mast cells in the grafts
was verified by staining with Giemsa stain and anti-human
mast cell tryptase antibodies (Chemicon, Temecula, CA; data
not shown).
IgE purified from BP-W7714 and BP-G5554 was injected
intradermally into the 2-week human skin grafts. Injection
volumes were kept constant at 100ml. Within 15 minutes
after injection of 6 ng of BP IgE, edema was noted within the
grafted skin. At 24 hours, an edematous, erythematous plaque
developed in all of the grafts that received IgE from either of
the BP sera (n¼ 11, Figure 2a and c). When the higher
amount of BP IgE (47 ng, n¼ 3) was injected into the graft,
erythema developed around the injection site within 5 minu-
tes, becoming much more intense at the 15-minute time
point. No swelling or erythema was noted in any of the
control grafts that received 6 ng of IgE isolated from normal
human serum (n¼ 9, Figure 2b and d) or in the surrounding
murine skin. To test whether the residual IgG remaining in the
BP IgE preparation was responsible for the observed changes,
we injected 1.25 ng of purified BP-W7714 IgG (approxi-
mately 4 to 5 times the amount of IgG present in the 6 ng dose
of BP IgE) into the human skin graft. The purified BP IgG
produced no clinical or histological evidence of disease (data
not shown). These results are summarized in Table 1.
Hematoxylin and eosin staining of the lesional grafts
showed congestion of the blood vessels in the upper dermis
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Figure 1. Purified BP IgE binds to basal epidermal keratinocytes and dermal
mast cells by IF, and to the NC16A region of BP180 by immunoblotting.
Following purification, IgE from serum BP-W7714 was tested by indirect
immunofluorescence for its ability to bind to components of human skin.
(a) A cryosection of normal human skin was labeled with the purified BP
IgE followed by FITC-anti-human IgE. Staining can be seen at the BMZ
(arrowheads), as well as on some dermal cells (arrows). (b) This is an
immunoblot of GST-NC16A fusion protein and GST (designated ‘‘N’’ and
‘‘G’’, respectively) labeled with either the unfractionated BP-W7714 serum
(left two lanes) or IgE purified from BP-W7714 (right two lanes). The
secondary antibody used for all four lanes was horseradish peroxidase-anti-
human IgE. The two arrowheads to the left of the blot indicate the positions of
GST-NC16A (upper) and GST (lower). IgE reactivity with the GST-NC16A
fusion protein is seen in the first and third lanes. Identical results were seen
with BP-G5554. Bar¼ 100mm.
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and a granulocytic infiltrate, which varied from sparse to
more dense near the margins of the grafts (Figure 3a and b).
The denser infiltrate was generally seen near the margins of
the grafts, where we had previously noted an increased
number of mast cells on Giemsa stain. At the higher dose of
IgE, microscopic separation at the BMZ was seen in two of
the three grafts (Figure 3c). The histological level of the blister
was mapped by indirect immunofluorescence using BPAG1-
and collagen VII-specific antibodies. BPAG1 and collagen VII
labeling were detected in the ceiling and floor of the IgE-
induced vesicle, respectively (Figure 3 e and f). This indicated
that the level of the split was in the lamina lucida, the same
site as lesional BP. Direct immunofluorescent staining
showed weak focal deposition of human IgE at the BMZ of
the graft and stronger staining on mast cells (Figure 4a and b).
No staining was seen with anti-human IgG or anti-murine C3
(Figure 4c and d). Electron microscopy identified mast cells
within the lesional region of the grafts (Figure 5a). Many of
the mast cells contained empty granules, indicating recent
degranulation. In addition, eosinophils, neutrophils, and
lymphocytes were also identified in the infiltrate (Figure 5b
and c).
DISCUSSION
Historically, the primary role for IgE class antibodies was in
the immune response in allergic and parasitic diseases.
Recently, a role for IgE and mast cells has been proposed in
the regulation of immune responses and in the development
of autoimmune disease (Frossi et al., 2004). This hypothesis is
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Figure 2. Human skin grafts injected with BP or control IgE. (a and c)
Grafts injected with 6 ng of BP IgE show a well-developed urticarial plaque
(11/11). (b and d) No elevation or erythema was seen, the control grafts
injected with 6 ng of normal IgE.
Table 1. Summary of passive transfer experiments
Injection No. of mice Inflammatory plaque
BP IgE, 6 ng 11 11/11
BP IgE, 47 ng 3 3/31
BP IgG, 1.25 ng 4 0/4
Control IgE, 6 ng 9 0/9
Control IgE, 47 ng 3 0/3
BMZ, basement membrane zone; BP, bullous pemphigoid.
1Two of the three grafts injected with 47 ng of BP IgE developed
histological separation at the BMZ.
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Figure 3. Histology of skin grafts injected with BP IgE. (a) The low-power
view of a human skin graft injected with 6 ng of BP IgE. Mild congestion of the
vessels is seen (arrow) and a granulocytic infiltrate. (b) Area of dense
infiltration showing the granulocytic character of the infiltrate. (c) Two of the
three human skin grafts receiving 47 ng of BP IgE split along the basement
membrane zone. (d) Control grafts that received normal IgE show no
abnormalities. Immunofluorescent mapping with antibodies to (e) BPAG1 and
(f) type VII collagen indicated the split was predominantly through the lamina
lucida/lamina densa region. Bar¼ 100 mm.
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supported by the recent identification of IgE class autoanti-
bodies in a number of autoimmune diseases, including
Grave’s disease and Hashimoto’s thyroiditis (Guo et al.,
1997, Sato et al., 1999), 3); however, the pathogenic
relevance of these IgE’s remains unknown. Elevated levels
of IgE have also been demonstrated in anti-SSA-positive
women with lupus who experience fetal loss, but again the
specificity of the IgE and any pathogenic role it plays have not
been determined (Sekigawa et al., 2004). In contrast, there is
a growing body of data regarding the specificity and potential
pathogenic role of IgE class autoantibodies in the organ-
specific autoimmune disease, BP (Provost and Tomasi, 1974;
Delaporte et al., 1996; Christophoridis et al., 2000; Dopp
et al., 2000, Chen et al., 2002, Dimson et al., 2003).
In this report, we showed that injection of BP IgE into
human skin grafts resulted in lesions that recapitulated the
clinical features of the urticarial lesions of BP, including the
presence of degranulated mast cells and eosinophils. In early
BP, the patients may have large urticarial plaques but
manifest few, if any, blisters. Sequential histological exam-
ination of the skin of BP patients during the development of
individual lesions has shown that mast cell degranulation is
the earliest event followed by migration of lymphocytes and
later eosinophils and neutrophils into the lesion (Wintroub
et al., 1978; Dvorak et al., 1982). Further evidence for mast
cell degranulation is the presence of eotaxin in the blister
fluid of BP lesions (Shrikhande et al., 2000).
The level of IgE used in these studies (60 ng/ml)
approximates the level of IgE present in normal human sera.
The higher level (470 ng/ml) is slightly above the normal
range of IgE, but approximates that seen in a larger group of
our BP patients (Dimson et al., 2003). Thus, the level of IgE
that we are testing in these experiments is within the
physiologic range.
The IgE isolation procedure used in the present investiga-
tion yielded greater than 10,000-fold purification of IgE
relative to IgG. The level of total IgG remaining in the BP IgE
purified preparations was in the range of 2–3 ng/ml. This
means that each 6 ng dose of BP IgE contained roughly 0.3 ng
of total IgG. To determine whether this level of IgG could be
responsible for the observed effects induced by our IgE
injections, we performed the same type of passive transfer
experiments using 1.25 ng of IgG purified from serum BP-
W7714. This key control demonstrated that BP IgG at this
concentration, which corresponds to approximately 4–5
times the amount of IgG present in the 6 ng dose of BP IgE,
did not trigger any detectable changes in the skin grafts. This
finding is supported by a previous report by Zillikens and co-
workers (Zillikens et al., 2001), who injected as much as
400mg of purified BP IgG (over 800,000 times greater than
the amount of IgG present in our BP IgE preparation) into
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Figure 4. IgE, IgG, and C3 labeling in grafts injected with BP IgE. Following
harvest of the grafts 24 hours after injection with 6 ng of BP IgE, cryosections
were labeled with FITC-conjugated anti-human IgE, IgG or anti-murine C3.
(a) Anti-human IgE revealed weak staining at the BMZ. (b) Mast cells were
also labeled by anti-IgE as indicated by double labeling with anti-human mast
cell tryptase. (c and d) No BMZ staining was seen with anti-human IgG or
anti-murine C3. Bar¼ 50mm.
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Figure 5. Electron micrographs of the infiltrate induced by BP IgE. The
infiltrate was composed of (a) mast cells, many of which have empty granules
(arrows), indicating recent degranulation. (b) Eosinophils, recognized by their
characteristic granules and bilobed nucleus, were also present, as were
(c) neutrophils and lymphocytes (data not shown). Bar¼ 1mm.
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human skin grafted onto SCID mice and detected no clinical
or histological lesions.
Another important control that we implemented was to
purify IgE from normal control sera and inject it into the
human skin grafts. This normal IgE was purified using the
same protocol that was used to purify BP IgE and was used at
the same dose as that used for the BP IgE. The control IgE
failed to induce any specific changes in the injected skin
grafts. This control rules out the possibility that the observed
changes in the skin grafts induced by our BP IgE injections
were non-specific effects of IgE or elements resulting from the
purification procedure. Based on the results of these controls,
it is clear that the changes that we observed in the human skin
grafts can be attributed to the IgE from the BP serum.
Although not directly tested in this study, it is probably that
the IgE antibodies responsible for the observed pathologic
response are directed against the keratinocyte surface protein,
BP180, or fragments of it formed by metabolic degradation. It
is well established that a high percentage of BP patients
produce anti-BP180 autoantibodies of both IgG and IgE
isotypes. Our research group has also recently shown that
these IgE autoantibodies largely target NC16A, the non-
collagenous linker region of this antigen’s ectodomain
(Fairley et al., 2005). Furthermore, antigen-specific degranu-
lation of circulating basophils from BP patients can be
elicited by treatment with the NC16A peptide (Dimson et al.,
2003). We therefore hypothesize that the mechanism for the
pathogenic reaction observed in our present human skin graft
model involves the binding of the injected BP IgE to the IgE
receptor on the surface of human dermal mast cells, and
degranulation of these cells after binding of the surface-
bound IgE to its antigenic target, thus releasing histamine and
other inflammatory mediators. The relatively weak staining
for IgE at the BMZ in the BP IgE-injected grafts when
compared to the staining seen on mast cells would support
this hypothesis. The stronger staining seen on the mast cells
may be due to higher affinity of the IgE for its receptor on
mast cells than for the BMZ.
It is known that a large stable fragment of the BP180
ectodomain is shed from the keratinocyte surface (Schacke
et al., 1998; Schumann et al., 2000). This 120 kDa shed form
could well serve as the antigenic activator in this pathogenic
process. The rapidity with which we saw a reaction (less than
5 minutes in the high-dose grafts) coupled with the electron
microscopy findings strongly support mast cell degranulation
as the mechanism for the early-phase lesion development in
the grafts. In addition to amplifying the inflammatory
reaction, the activated mast cells also release proteases that
could well contribute directly to dermal–epidermal separa-
tion.
Another possible component of the BP IgE-mediated
response may involve the binding of IgE to BP180 on the
surface of basal keratinocytes. This binding could impair
BP180 function directly, or, more likely, initiate a pro-
inflammatory signaling cascade. One concern with this
scenario is that IgG would ‘‘out compete’’ for the available
binding sites on BP180, diminishing the importance of IgE
autoantibodies. Another is that the staining for IgE seen in our
model was weak compared to that on mast cells. Our
research group has recently initiated a study directed at the
quantification and comparison of BP180-specific IgE and IgG
levels in BP. In the material utilized in this study, the
concentrations of circulating BP180-specific IgE and IgG
were similar (6–9 and 24 mg/ml, respectively; unpublished
observations), although the relative avidities were not
measured. More work is needed to determine the plausibility
of this type of IgE-mediated effect on keratinocytes in the
pathogenesis of BP.
Complement fixation at the BMZ, a characteristic immuno-
pathologic finding in BP, was one feature absent in
our BP IgE-injected grafts. Since IgE does not activate
complement, this was not unexpected. Clearly, IgE alone is
not capable of replicating all of the pathologic features of
BP. Previous work from our laboratory and others point
to IgG class autoantibodies directed against BP180 as
the trigger for complement fixation at the BMZ and for
the subsequent recruitment of inflammatory cells involved
in dermal–epidermal separation (Liu et al., 1993, 1995;
Chen et al., 2002; Sitaru et al., 2002). Just as in the case
of IgE, it is also clear that IgG alone cannot account for all
of the pathologic features of BP. Conspicuously absent
from the IgG passive transfer model are the key
changes associated with the urticarial stage of BP. It is highly
likely that the clinical and immunohistochemical manifesta-
tions we see in patients represent the effects of both IgE and
IgG class autoantibodies.
In a previous report, we demonstrated that the fine
specificities exhibited by the IgG and IgE class autoantibodies
are quite similar, and thus are likely to have arisen via clonal
selection (Fairley et al., 2005). After an initial humoral
immune response, which is typically IgM, cytokine-mediated
DNA recombination events can occur leading to a switch in
the isotype, while largely maintaining the antigen-binding
properties. Subtle changes in the binding affinity to the target
antigen can occur during isotype switching via somatic
hypermutation of the complementarity determining region
(Chaudhuri and Alt, 2004). Owing to the chromosomal
positions of the g and e genes, a class switch from IgG to IgE is
possible, while the reverse is not. Production of IgE requires
the cytokines IL-4 and -13 as well as ligation of CD40 to
CD40L on B cells (reviewed in Prussin and Metcalfe, 2003).
The findings of this study represent early evidence
pathogenicity of IgE autoantibodies. We showed that injec-
tion of BP IgE into human skin grafts resulted in lesions that
produced urticarial plaques characterized by the presence of
degranulated mast cells. The degranulation of mast cells
recapitulated the earliest events of lesion development
reported by previous investigators (Wintroub et al., 1978;
Dvorak et al., 1982). The presence of pathogenic IgE
autoantibodies may be indicative of the type of initial trigger
which leads to this disease or the manner in which the
antigen is presented to the immune system. BP provides a
unique opportunity to study further the role of IgE in
autoimmunity. These findings may also open up new areas
for potential therapeutic intervention in BP or other human
autoimmune diseases.
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Addendum: While this paper was under review, Nishie
et al. (2007) have published an additional murine model of
BP. This model utilizes human BP IgG in a humanized mouse
that expresses the human BP180 protein. Detachment of the
epidermis was seen in animals injected with BP IgG;
however, like other models, the urticarial plaques and
eosinophilia characteristic of BP were absent.
MATERIALS AND METHODS
Characterization of IgE and IgG in BP and normal sera
This study was approved by the Human Research Review Committee
of the Medical College of Wisconsin Affiliated Hospitals (no. 230-
01) and the VA Medical Center and was performed in adherence to
the Declaration of Helsinki Principles. Consent was obtained from
all patients. Levels of total IgE and IgG were measured by capture
ELISA (Bethyl Labs, Montgomery, TX).
Purification of BP IgE and BP IgG
IgE was purified from BP sera BP-W7714 and BP-G5554 using a
multistep process modified from Kleine-Tebbe et al. (1995). Serum
was diluted 1:1 in phosphate-buffered saline and the IgG was
removed by multiple passes over a protein G affinity column (Pierce,
Rockford, IL). By indirect immunofluorescence, the titers of IgG
directed against the BMZ went from 1:2,560 and 1:1,280, respec-
tively, in the starting sera to undetectable following the protein G
column. The resulting IgG-depleted fraction was incubated with an
e-chain-specific monoclonal anti-human IgE coupled to Affi-Gel HZ
or Affigel-10 (Bio-Rad, Hercules, CA) and eluted with 25 mM
triethylamine pH 11.2 with 1% BSA, and immediately neutralized.
The IgE-containing eluate was extensively dialyzed against sterile
phosphate-buffered saline and concentrated. BP IgG was purified by
affinity chromatography utilizing a protein G affinity column (Pierce).
The IgG was eluted with 0.1 M glycine pH 2–3 and immediately
neutralized with 1 M Tris pH 8.0. The IgG was extensively dialyzed
against sterile phosphate-buffered saline (pH 7.4). The IgG and IgE
concentrations were determined by ELISA (Bethyl Labs).
Injection of BP IgE into human skin grafts
These experiments were approved by Animal Studies Subcommittee
(VA2655-02P). A 2 2 cm area of skin was removed from the back
of 6-week-old nu/nu mice. A similar sized piece of human skin
obtained from reduction mammoplasties was grafted onto the back
of the mice. After 14 days, the expression of BMZ proteins in the
graft was tested by indirect immunofluorescence utilizing antibodies
directed against collagen VII (gift of Drs Mei Chen and David
Woodley, University of Southern California), laminin 5 (gift of Kim
Yancey, Medical College of Wisconsin) or BP180 (Liu et al., 1995).
The presence of mast cells in the graft was determined with Giemsa
stain, and their human origin was established by direct IF utilizing
anti-human mast cell tryptase (Chemicon, Temecula, CA) and
techniques as described previously (Dimson et al., 2003).
One hundred microliters of BP IgE (60 ng/ml, n¼ 11 or 470 ng/
ml, n¼ 3) was injected into 14-day human skin grafts on nu/nu mice.
Controls included normal human IgE purified by our laboratory in
the same manner as BP IgE (n¼ 9). Non-specific human IgE (http://
www.diatec.com, Oslo, Norway) was also tested at the high
concentration, 47mg per graft (n¼ 3). The commercial IgE was used
for the more concentrated injection, since concentration of the IgE
we isolated from normal sera would also have increased the
concentration of any contaminants from the purification scheme that
could affect our injections. The grafts were harvested 24 hours after
injection and fixed for routine histology, direct immunofluorescence,
and electron microscopy. Electron microscopy was performed in the
Electron Microscopy Facility at the Medical College of Wisconsin.
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